Med­Tech indus­try: Spe­cial path of Ger­ma­ny and Switzerland!

MRA bet­ween EU and Switz­er­land: Does it con­ti­nue to app­ly or not?

Our last news on the MRA bet­ween the EU and Switz­er­land was enti­t­led: “Mutu­al Reco­gni­ti­on Agree­ment bet­ween Switz­er­land and the EU falls through.”

In the mean­ti­me, the­re is dis­agree­ment among pro­mi­nent play­ers in the Swiss med­tech indus­try about the legal­ly valid ces­sa­ti­on of the old agree­ment. In addi­ti­on, indus­try repre­sen­ta­ti­ves on both the Ger­man and Swiss sides have spo­ken out in favour of coö­pe­ra­ti­on that the EU Com­mis­si­on does not envisage.

Who says what?

First, the­re seems to be agree­ment that the Mutu­al Reco­gni­ti­on Agree­ment (MRA) bet­ween EU mem­ber sta­tes and Switz­er­land has not been updated. As a result, the Swiss medi­cal tech­no­lo­gy indus­try lost access – also accord­ing to the view held by reu­sch­law – to a sta­te that was put on an equal foo­ting with the EU mem­ber sta­tes when the EU Medi­cal Tech­no­lo­gy Regu­la­ti­on (MDR) came into for­ce. Switz­er­land beca­me a “third coun­try” with all the atten­dant adver­se con­se­quen­ces for eco­no­mic actors in the EU and Switz­er­land.

The Swiss Federal Office of Public Health (FOPH) and the Swiss regu­la­to­ry aut­ho­ri­ty Swiss­me­dic still take the posi­ti­on that the old MRA is not lon­ger app­li­ca­ble becau­se no update has been made.

The Swiss Federal Coun­cil takes the oppo­si­te view. In its view, the old MRA con­ti­nues to app­ly even though it has not been updated. An ans­wer of the Federal Coun­cil of 13 Decem­ber 2021 to a ques­ti­on sub­mit­ted to the Natio­nal Coun­cil reads ver­ba­tim as fol­lows: “The Mutu­al Reco­gni­ti­on Agree­ment (MRA) con­ti­nues to app­ly”.

The view of the Swiss Federal Coun­cil is shared in par­ti­cu­lar by the Swiss indus­try asso­cia­ti­on Swiss Med­Tech, which on the one hand had con­sist­ent­ly vehe­ment­ly advo­ca­ted the updating of the MRA and on the other hand per­sist­ent­ly empha­sis­ed the mul­ti­tu­de of con­se­quen­ces asso­cia­ted with the “third coun­try sta­tus” for eco­no­mic actors. A legal opi­ni­on com­mis­sio­ned by Swiss Med­Tech comes to the con­clu­si­on – as does the Swiss Federal Coun­cil – that the old MRA is still valid and app­li­ca­ble. “It was neit­her ter­mi­na­ted nor sus­pen­ded by means of noti­fi­ca­ti­on”. The expert opi­ni­on can be acces­sed via the Swiss Med­Tech home­page.

Bila­te­ral coö­pe­ra­ti­on bet­ween Switz­er­land and Germany?

In a press release dated 26 May 2021 the EU Com­mis­si­on infor­med that fol­lowing the fail­u­re of nego­tia­ti­ons to update the old MRA bet­ween the EU and Switz­er­land, “mutu­al reco­gni­ti­on and rela­ted tra­de faci­li­ta­ti­on for medi­cal devices bet­ween the EU and Switz­er­land will no lon­ger app­ly as of 26 May. This is rela­ted to the new Medi­cal Devices Regu­la­ti­on, which comes into for­ce in the EU on the same day”.

The pro­po­sal to pro­vi­de for a limi­ted amend­ment to the Mutu­al Reco­gni­ti­on Agree­ment as a pre­cau­tio­na­ry mea­su­re to allow a tran­si­ti­on peri­od for exis­ting Swiss cer­ti­fi­ca­tes of con­for­mi­ty until (at most) 26 May 2024, during which time exis­ting cer­ti­fi­ca­tes issued in the EU would also remain valid, was not imple­men­ted until 26 May 2021. As a result, the EU Com­mis­si­on con­clu­ded, among other things, that exis­ting cer­ti­fi­ca­tes (so-called “SQS cer­ti­fi­ca­tes”) issued by a noti­fied body domic­i­led in Switz­er­land would no lon­ger be reco­gnis­ed by the EU.

As sta­ted abo­ve, the Swiss indus­try asso­cia­ti­on Swiss Med­Tech (as well as the Swiss Federal Coun­cil) is of the opi­ni­on that the old MRA is still valid and should be app­lied. But then the EU Com­mis­si­on vio­la­tes the app­li­ca­ble law with regard to exis­ting SQS cer­ti­fi­ca­tes: Assuming the vali­di­ty of the MRA, the exis­ting cer­ti­fi­ca­tes are to be reco­gnis­ed regard­less of the date of app­li­ca­ti­on of the MDR in the EU mem­ber states.

Swiss MedTech’s posi­ti­on is sup­por­ted among others by renow­ned Ger­man indus­try repre­sen­ta­ti­ves, first and fore­mo­st BVMed. Accord­ing to Swiss Med­Tech, BVMed has con­ta­c­ted the AG MP (Medi­cal Devices Working Group of the Supre­me Sta­te Health Aut­ho­ri­ties). The board of the ZLG is con­cer­ned with pro­blems of the enfor­ce­ment of medi­cal device law and here in par­ti­cu­lar with the coör­di­na­ti­on of the coö­pe­ra­ti­on of the coun­tries. Accord­ing to the assess­ment of the Working Group, the SQS cer­ti­fi­ca­ti­ons of the Swiss bodies still noti­fied in accordance with Direc­ti­ves 90/385/EEC and 93/42/EEC (PDF) con­ti­nue to be valid until the dead­lines set out in Arti­cle 120(2) MDR. This means that Swiss manu­fac­tu­rers may con­ti­nue to sell their MDD pro­ducts with SQS cer­ti­fi­ca­tes in Ger­ma­ny. Howe­ver, an EC REP must be appoin­ted for the­se pro­ducts as a prerequisite.

Thus, it seems clear (for the time being) that “spe­cial con­di­ti­ons” app­ly to the coö­pe­ra­ti­on bet­ween Switz­er­land and Ger­ma­ny. One con­se­quence of this is that this excep­ti­on can­not auto­ma­ti­cal­ly app­ly to the other EU mem­ber sta­tes, which con­tra­dicts the idea of har­mo­ni­sa­ti­on and the princi­ples of the free inter­nal mar­ket per se. It remains to be seen what result the Euro­pean Court of Jus­ti­ce, which has alrea­dy dealt with the ques­ti­on of the con­ti­nued vali­di­ty of SQS cer­ti­fi­ca­tes in all mem­ber sta­tes, will come to.

Recom­men­da­ti­on for action

Based on a fail­u­re of the MRA, reuschlaw’s recom­men­da­ti­on for action to dis­tri­bu­tors of medi­cal devices manu­fac­tu­red in Switz­er­land was to be awa­re that they could (unin­ten­tio­nal­ly) beco­me importers and would have to com­ply with the legal obli­ga­ti­ons of importers of medi­cal devices. Con­ver­se­ly, Euro­pean manu­fac­tu­rers of medi­cal devices and dis­tri­bu­tors with sales acti­vi­ties in Switz­er­land were advi­sed to seek and man­da­te a Swiss Rep wit­hin the app­li­ca­ble desi­gna­ti­on peri­od. This is still a pos­si­ble option.

On the other hand, eco­no­mic actors are in qui­te pro­mi­nent com­pa­ny with the Swiss Federal Coun­cil, Swiss Med­Tech and a sup­ple­men­ta­ry legal opi­ni­on when they take the posi­ti­on that the old MRA still app­lies and hence the known legal frame­work con­ti­nues to app­ly to the coö­pe­ra­ti­on of Swiss com­pa­nies and eco­no­mic actors of EU mem­ber states.

To end in the words of Swiss Med­Tech: “Each com­pa­ny must exami­ne [pen­ding the ECJ’s decisi­on] for its­elf the extent to which it takes into account the offi­cial posi­ti­on of the Federal Coun­cil as well as the avail­ab­le legal opi­ni­ons in its busi­ness decisions”.


Stay up-to-date

We use your e-mail address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.